
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is positioned favorably, benefiting from the growing diagnosis of sleep apnea and an aging population, contributing to a structurally expanding market for its respiratory care devices. The company's strong financial performance is evidenced by a 12% year-over-year increase in revenue from masks and other products in the U.S., Canada, and Latin America, while also maintaining a strategy to return cash to shareholders through increased dividends and share repurchase initiatives. Furthermore, ResMed's commitment to invest in digital health solutions aims to enhance its market differentiation and support ongoing growth, indicating a solid outlook for revenue expansion alongside rising operating expenses.
Bears say
The analysis of ResMed indicates a negative outlook, primarily due to concerns about medium-term disruptions in Positive Airway Pressure (PAP) volumes attributed to the uptake of GLP-1 medications for treating obesity-related conditions. Furthermore, while ResMed is currently outpacing market growth, the potential impact of these medications on demand for masks and devices raises significant apprehension regarding future revenue streams. This situation is convoluted by ResMed's dependency on the Americas for approximately two-thirds of its revenue, making the company particularly vulnerable to shifts in healthcare trends related to sleep apnea treatment.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares